Aslan Pharmaceuticals Ltd.
(NASDAQ : ASLN)

( )
ASLN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.41%202.721.3%$426.59m
BIIBBiogen Inc.
-2.46%220.061.3%$391.11m
GILDGilead Sciences, Inc.
-0.49%64.910.9%$378.65m
CELGCelgene Corporation
1.13%102.951.3%$367.47m
ILMNIllumina, Inc.
-0.36%309.443.5%$247.45m
REGNRegeneron Pharmaceuticals, Inc.
-0.46%300.192.6%$218.58m
EXASExact Sciences Corporation
-0.95%96.4724.1%$199.33m
VRTXVertex Pharmaceuticals Incorporated
-0.84%176.231.9%$176.44m
ALXNAlexion Pharmaceuticals, Inc.
-1.58%98.412.0%$169.95m
AAgilent Technologies, Inc.
-0.44%74.591.6%$143.57m
SRPTSarepta Therapeutics, Inc.
-1.91%85.7714.6%$132.47m
BMRNBioMarin Pharmaceutical Inc.
1.84%69.154.3%$96.30m
SGENSeattle Genetics, Inc.
1.70%87.406.2%$95.18m
NKTRNektar Therapeutics
-2.81%17.275.5%$84.77m
ALDRAlder Biopharmaceuticals, Inc.
0.11%18.9210.2%$81.63m

Company Profile

Aslan Pharmaceuticals Ltd. is a clinical-stage oncology-focused biopharmaceutical company, which engages in the development of novel therapeutics. Its pipeline includes varlitinib, ASLAN003, ASLAN004, and ASLAN002. The firm's portfolio focuses on validated growth pathways applied to new patient segments, novel immune checkpoints, and novel cancer metabolic pathways. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.